

Press Release November 8, 2017

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018

The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect representative to be a member of the Nomination Committee together with the Chairman of the Board. In the establishment of the Nomination Committee, the ownership ratios as of June 30, 2017 shall determine the largest shareholders in terms of voting rights. The representative of the largest shareholder in the Nomination Committee at that time shall be the chairman of the election committee. If any of the three largest shareholders waives their right to appoint a member of the Nomination Committee, the next largest shareholder shall be allowed to appoint a member of the Nomination Committee.

In accordance with the AGM's decision, the Nomination Committee was formed and consists of, apart from the chairman of Infant Bacterial Therapeutics AB's Board of Directors, Peter Rothschild, by Per-Erik Andersson, representative of the company's largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, representative of the company's second largest shareholder Banque Öhman SA as well as Jannis Kitsakis, representative of the company's third largest shareholder, the Fourth Swedish National Pension Fund. All members of the Nomination Committee, apart from Peter Rothschild, are independent in relation to the company and company management.

The nomination committee is reached via the election committee chairman, Per-Erik Andersson, at pea@pealaw.se, or by telephone: +46 70-537 98 92.

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of *Lactobacillus reuteri*, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.
www.ibtherapeutics.com

For additional information please contact

Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com